NM_000077.5(CDKN2A):c.122C>T (p.Pro41Leu) AND Hereditary cancer-predisposing syndrome

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: May 28, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002369188.3

Allele description [Variation Report for NM_000077.5(CDKN2A):c.122C>T (p.Pro41Leu)]

NM_000077.5(CDKN2A):c.122C>T (p.Pro41Leu)

Gene:

CDKN2A:cyclin dependent kinase inhibitor 2A [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

9p21.3

Genomic location:

Preferred name:

NM_000077.5(CDKN2A):c.122C>T (p.Pro41Leu)

HGVS:

NC_000009.12:g.21974706G>A
NG_007485.1:g.24786C>T
NM_000077.5:c.122C>TMANE SELECT
NM_001195132.2:c.122C>T
NM_001363763.2:c.-3-3498C>T
NM_058195.4:c.194-3498C>T
NM_058197.5:c.122C>T
NP_000068.1:p.Pro41Leu
NP_000068.1:p.Pro41Leu
NP_001182061.1:p.Pro41Leu
NP_478104.2:p.Pro41Leu
LRG_11t1:c.122C>T
LRG_11:g.24786C>T
LRG_11p1:p.Pro41Leu
NC_000009.11:g.21974705G>A
NM_000077.4:c.122C>T

Protein change:

P41L

Molecular consequence:

NM_001363763.2:c.-3-3498C>T - intron variant - [Sequence Ontology: SO:0001627]
NM_058195.4:c.194-3498C>T - intron variant - [Sequence Ontology: SO:0001627]
NM_000077.5:c.122C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_001195132.2:c.122C>T - missense variant - [Sequence Ontology: SO:0001583]
NM_058197.5:c.122C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Hereditary cancer-predisposing syndrome
Synonyms:: Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002666958	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (May 28, 2024)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002666958

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(May 28, 2024)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV002666958.3

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.P41L variant (also known as c.122C>T), located in coding exon 1 of the CDKN2A gene, results from a C to T substitution at nucleotide position 122. The proline at codon 41 is replaced by leucine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Aug 11, 2024

ClinVar

Relating variation to medicine